Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company, will participate in the second annual Oncology Venture, Innovation, and Partnering Summit in Boston on September 29-30, 2025. CEO Eric Poma will engage in a fireside chat with Ladenburg Thalmann's Dr. Aydin Huseynov on September 30 at 10:10 a.m. ET.
The presentation will showcase Calidi's RedTail platform, designed to protect viruses from immune clearance, induce tumor lysis, and deliver genetic medicines to metastatic sites through systemic administration. Dr. Poma will also be available for one-on-one meetings with conference attendees.
Calidi Biotherapeutics (NYSE American: CLDI), un’azienda biotech in fase clinica, parteciperà al secondo Oncology Venture, Innovation e Partnering Summit a Boston il 29-30 settembre 2025. Il CEO Eric Poma parteciperà a un fireside chat con il Dr. Aydin Huseynov di Ladenburg Thalmann il 30 settembre alle 10:10 ET. La presentazione metterà in luce la piattaforma RedTail di Calidi, progettata per proteggere i virus dall’eliminazione immunitaria, indurre la lisi tumorale e consegnare farmaci genetici ai siti metastatici tramite somministrazione sistemica. Il Dr. Poma sarà inoltre disponibile per incontri individuali con i partecipanti alla conferenza.
Calidi Biotherapeutics (NYSE American: CLDI), una empresa de biotecnología en fase clínica, participará en la segunda Cumbre Anual de Oncology Venture, Innovation y Partnering en Boston los días 29 y 30 de septiembre de 2025. El CEO Eric Poma participará en un fireside chat con el Dr. Aydin Huseynov de Ladenburg Thalmann el 30 de septiembre a las 10:10 a.m. ET. La presentación mostrará la plataforma RedTail de Calidi, diseñada para proteger a los virus de la eliminación por el sistema inmunitario, inducir la lisis tumoral y entregar medicamentos genéticos a sitios metastáticos mediante administración sistémica. El Dr. Poma también estará disponible para reuniones individualizadas con los asistentes a la conferencia.
Calidi Biotherapeutics(NYSE American: CLDI)는 임상 단계의 바이오텍 기업으로, 2025년 9월 29-30일 보스턴에서 열리는 제2회 Oncology Venture, Innovation 및 Partnering Summit에 참여합니다. CEO 에릭 포마는 Ladenburg Thalmann의 Dr. Aydin Huseynov와 9월 30일 동부 표준시 10:10에 fireside chat를 진행합니다. 발표는 바이러스가 면역 체계에 의한 제거로부터 보호되고, 종양 용해를 유도하며, 전신 투여를 통해 전이 부위에 유전 약물을 전달하도록 설계된 Calidi의 RedTail 플랫폼을 선보일 예정입니다. 포마 박사는 컨퍼런스 참가자들과의 1:1 미팅도 가능하다고 전합니다.
Calidi Biotherapeutics (NYSE American: CLDI), entreprise de biotechnologie en phase clinique, participera au deuxième sommet annuel Oncology Venture, Innovation et Partnering à Boston les 29 et 30 septembre 2025. Le PDG Eric Poma participera à une discussion au coin du feu avec le Dr Aydin Huseynov de Ladenburg Thalmann le 30 septembre à 10h10, heure de l’Est. La présentation mettra en lumière la plateforme RedTail de Calidi, conçue pour protéger les virus de l’élimination par le système immunitaire, induire la lyse tumorale et délivrer des médicaments génétiques vers des sites métastatiques par administration systémique. Le Dr Poma sera également disponible pour des réunions en tête-à-tête avec les participants à la conférence.
Calidi Biotherapeutics (NYSE American: CLDI), ein in der klinischen Phase befindliches Biotech-Unternehmen, wird am zweiten jährlichen Oncology Venture, Innovation und Partnering Summit in Boston am 29. und 30. September 2025 teilnehmen. CEO Eric Poma wird am 30. September um 10:10 Uhr ET ein Fireside-Chat-Gespräch mit Dr. Aydin Huseynov von Ladenburg Thalmann führen. Die Präsentation wird Calidis RedTail-Plattform vorstellen, die darauf abzielt, Viren vor der Immunabwehr zu schützen, Tumorlyse zu induzieren und genetische Medikamente durch systemische Verabreichung an metastatische Standorte zu liefern. Dr. Poma wird auch für Einzelgespräche mit Konferenzteilnehmern zur Verfügung stehen.
Calidi Biotherapeutics (NYSE American: CLDI)، شركة تقانة حيوية في مرحلةClinical ستشارك في القمة السنوية الثانية Oncology Venture, Innovation, and Partnering Summit في بوسطن في 29-30 سبتمبر 2025. سيشارك المدير التنفيذي إيريك بومة في جلسة Fireside Chat مع الدكتور أيدين حسينوف من Ladenburg Thalmann في 30 سبتمبر الساعة 10:10 صباحاً بتوقيت شرق الولايات المتحدة. ستعرض العرض منصة RedTail من Calidi، المصممة لحماية الفيروسات من الإزالة المناعية، وتحفيز تفتيت الورم، وتوصيل الأدوية الوراثية إلى مواقع النقائل عبر الإعطاء النظامي. سيكون الدكتور بومة متاحاً أيضاً لعقد اجتماعات فردية مع الحضور.
Calidi Biotherapeutics（NYSE American: CLDI），一家处于临床阶段的生物技术公司，将于2025年9月29-30日在波士顿举行的第二届 Oncology Venture、Innovation 与 Partnering Summit 参加。CEO Eric Poma 将于9月30日美东时间上午10:10与 Ladenburg Thalmann 的 Aydin Huseynov 博士进行炉边对话。此次演讲将展示 Calidi 的 RedTail 平台，该平台旨在保护病毒不被免疫系统清除、诱导肿瘤裂解，并通过系统给药将遗传药物输送到转移部位。Poma 博士还将为大会与会者提供一对一会谈。
- None.
- None.
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced that its management will participate in the second annual Oncology Venture, Innovation, and Partnering Summit being held September 29-30, 2025, at the Westin Boston Seaport in Boston, MA.
Eric Poma, Ph.D., Chief Executive Officer, will participate in a fireside chat with Dr. Aydin Huseynov, Managing Director and Senior Analyst at Ladenburg Thalmann, on the intersection of science and capital to develop and advance effective cancer treatments on September 30, 2025, at 10:10 a.m. E.T. Dr. Poma’s presentation will highlight Calidi’s RedTail platform, which is engineered to protect virus from immune clearance and induce tumor lysis and deliver potent therapeutic genetic medicines to metastatic sites through systemic administration.
Dr. Poma will be available to participate in one-on-one meetings with participants registered to attend the conference.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.
The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications.
Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here.
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s annual report filed with the SEC on Form 10-K on March 31, 2025, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
For Investors:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
CLDI@redchip.com
FAQ
When is Calidi Biotherapeutics (CLDI) presenting at the Oncology Summit in Boston?
What will Calidi Biotherapeutics (CLDI) discuss at the 2025 Oncology Summit?
Who will be presenting for Calidi Biotherapeutics (CLDI) at the 2025 Oncology Summit?
Where is the 2025 Oncology Venture, Innovation, and Partnering Summit being held?
